Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits their availability for those who need them. Part of the reason for the cost ...

BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing Key funding milestone will power the company's push to replace trial-and-error process ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for advanced therapeutics. Artis officially emerged from stealth on Wednesday, ...

In the complex process of producing a gene therapy, bioprocessors depend on assays to monitor the attributes of the product at various stages. Scientists at Thermo Fisher Scientific focus on ...

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific ...

GERMANTOWN, MD / ACCESS Newswire / March 16, 2026 / uBriGene Biosciences (uBriGene), a global CDMO leader, is excited to ...

U.S. Cell and Gene Therapy CDMO Market is projected to grow from USD 2.09 Billion in 2025 to USD 10.28 Billion by 2035 due to expanding gene and cell therapy pipelines globallyAustin, March 06, 2026 ...

Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying ...